Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer

Dan Wang, Li Zhong, Mengxin Li, Jia Li, Karen Tran, Lingzhi Ren, Ran He, Jun Xie, Richard P. Moser, Cara Fraser, Tim Kuchel, Miguel Sena-Esteves, Terence R. Flotte, Neil Aronin, Guangping Gao

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pre-existing neutralizing antibody (NAb) against adeno-associated virus (AAV) commonly found in primates is a major host barrier that can severely compromise in vivo gene transfer by AAV vectors. To achieve proof-of-concept success in clinical development of recombinant AAV (rAAV)-based in vivo gene therapy, it is crucial to consider the potential interference of NAb and to enroll serologically compatible study subjects. In this study, we report a large AAV NAb dataset comprising multiple large animal species and AAV serotypes and compare two NAb assays based on in vitro or in vivo transduction inhibition, respectively. Together with previously published AAV seroepidemiology studies, these data can serve as a reference for selecting suitable serotypes, study subjects of large animal species, and potentially human patients for rAAV treatment. In addition, we modeled the intrathalamus rAAV9 delivery in the presence of circulating anti-AAV9 NAb generated by either pre-immunization or passive transfer of NAb-positive large animal serum to mice. The data showed that circulating NAb may not be the sole determinant to inhibit brain transduction. Other aspects of pre-existing AAV immunity following natural infection or rAAV administration may be further studied to establish a more accurate inclusion criterion for clinical studies employing intraparenchymal rAAV9 injections.

LanguageEnglish
Pages65-72
Number of pages8
JournalMolecular Therapy - Methods and Clinical Development
Volume11
DOIs
Publication statusPublished - 14 Dec 2018

Keywords

  • CNS gene transfer
  • adeno-associated virus
  • gene therapy
  • large animals
  • neutralizing antibody

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Wang, Dan ; Zhong, Li ; Li, Mengxin ; Li, Jia ; Tran, Karen ; Ren, Lingzhi ; He, Ran ; Xie, Jun ; Moser, Richard P. ; Fraser, Cara ; Kuchel, Tim ; Sena-Esteves, Miguel ; Flotte, Terence R. ; Aronin, Neil ; Gao, Guangping. / Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer. In: Molecular Therapy - Methods and Clinical Development. 2018 ; Vol. 11. pp. 65-72.
@article{7fa0e02c59454bcc84ee85dfb28955d5,
title = "Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer",
abstract = "Pre-existing neutralizing antibody (NAb) against adeno-associated virus (AAV) commonly found in primates is a major host barrier that can severely compromise in vivo gene transfer by AAV vectors. To achieve proof-of-concept success in clinical development of recombinant AAV (rAAV)-based in vivo gene therapy, it is crucial to consider the potential interference of NAb and to enroll serologically compatible study subjects. In this study, we report a large AAV NAb dataset comprising multiple large animal species and AAV serotypes and compare two NAb assays based on in vitro or in vivo transduction inhibition, respectively. Together with previously published AAV seroepidemiology studies, these data can serve as a reference for selecting suitable serotypes, study subjects of large animal species, and potentially human patients for rAAV treatment. In addition, we modeled the intrathalamus rAAV9 delivery in the presence of circulating anti-AAV9 NAb generated by either pre-immunization or passive transfer of NAb-positive large animal serum to mice. The data showed that circulating NAb may not be the sole determinant to inhibit brain transduction. Other aspects of pre-existing AAV immunity following natural infection or rAAV administration may be further studied to establish a more accurate inclusion criterion for clinical studies employing intraparenchymal rAAV9 injections.",
keywords = "CNS gene transfer, adeno-associated virus, gene therapy, large animals, neutralizing antibody",
author = "Dan Wang and Li Zhong and Mengxin Li and Jia Li and Karen Tran and Lingzhi Ren and Ran He and Jun Xie and Moser, {Richard P.} and Cara Fraser and Tim Kuchel and Miguel Sena-Esteves and Flotte, {Terence R.} and Neil Aronin and Guangping Gao",
year = "2018",
month = "12",
day = "14",
doi = "10.1016/j.omtm.2018.09.003",
language = "English",
volume = "11",
pages = "65--72",
journal = "Molecular Therapy - Methods and Clinical Development",
issn = "2329-0501",
publisher = "Cell Press",

}

Wang, D, Zhong, L, Li, M, Li, J, Tran, K, Ren, L, He, R, Xie, J, Moser, RP, Fraser, C, Kuchel, T, Sena-Esteves, M, Flotte, TR, Aronin, N & Gao, G 2018, 'Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer', Molecular Therapy - Methods and Clinical Development, vol. 11, pp. 65-72. https://doi.org/10.1016/j.omtm.2018.09.003

Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer. / Wang, Dan; Zhong, Li; Li, Mengxin; Li, Jia; Tran, Karen; Ren, Lingzhi; He, Ran; Xie, Jun; Moser, Richard P.; Fraser, Cara; Kuchel, Tim; Sena-Esteves, Miguel; Flotte, Terence R.; Aronin, Neil; Gao, Guangping.

In: Molecular Therapy - Methods and Clinical Development, Vol. 11, 14.12.2018, p. 65-72.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer

AU - Wang, Dan

AU - Zhong, Li

AU - Li, Mengxin

AU - Li, Jia

AU - Tran, Karen

AU - Ren, Lingzhi

AU - He, Ran

AU - Xie, Jun

AU - Moser, Richard P.

AU - Fraser, Cara

AU - Kuchel, Tim

AU - Sena-Esteves, Miguel

AU - Flotte, Terence R.

AU - Aronin, Neil

AU - Gao, Guangping

PY - 2018/12/14

Y1 - 2018/12/14

N2 - Pre-existing neutralizing antibody (NAb) against adeno-associated virus (AAV) commonly found in primates is a major host barrier that can severely compromise in vivo gene transfer by AAV vectors. To achieve proof-of-concept success in clinical development of recombinant AAV (rAAV)-based in vivo gene therapy, it is crucial to consider the potential interference of NAb and to enroll serologically compatible study subjects. In this study, we report a large AAV NAb dataset comprising multiple large animal species and AAV serotypes and compare two NAb assays based on in vitro or in vivo transduction inhibition, respectively. Together with previously published AAV seroepidemiology studies, these data can serve as a reference for selecting suitable serotypes, study subjects of large animal species, and potentially human patients for rAAV treatment. In addition, we modeled the intrathalamus rAAV9 delivery in the presence of circulating anti-AAV9 NAb generated by either pre-immunization or passive transfer of NAb-positive large animal serum to mice. The data showed that circulating NAb may not be the sole determinant to inhibit brain transduction. Other aspects of pre-existing AAV immunity following natural infection or rAAV administration may be further studied to establish a more accurate inclusion criterion for clinical studies employing intraparenchymal rAAV9 injections.

AB - Pre-existing neutralizing antibody (NAb) against adeno-associated virus (AAV) commonly found in primates is a major host barrier that can severely compromise in vivo gene transfer by AAV vectors. To achieve proof-of-concept success in clinical development of recombinant AAV (rAAV)-based in vivo gene therapy, it is crucial to consider the potential interference of NAb and to enroll serologically compatible study subjects. In this study, we report a large AAV NAb dataset comprising multiple large animal species and AAV serotypes and compare two NAb assays based on in vitro or in vivo transduction inhibition, respectively. Together with previously published AAV seroepidemiology studies, these data can serve as a reference for selecting suitable serotypes, study subjects of large animal species, and potentially human patients for rAAV treatment. In addition, we modeled the intrathalamus rAAV9 delivery in the presence of circulating anti-AAV9 NAb generated by either pre-immunization or passive transfer of NAb-positive large animal serum to mice. The data showed that circulating NAb may not be the sole determinant to inhibit brain transduction. Other aspects of pre-existing AAV immunity following natural infection or rAAV administration may be further studied to establish a more accurate inclusion criterion for clinical studies employing intraparenchymal rAAV9 injections.

KW - CNS gene transfer

KW - adeno-associated virus

KW - gene therapy

KW - large animals

KW - neutralizing antibody

UR - http://www.scopus.com/inward/record.url?scp=85055538821&partnerID=8YFLogxK

U2 - 10.1016/j.omtm.2018.09.003

DO - 10.1016/j.omtm.2018.09.003

M3 - Article

VL - 11

SP - 65

EP - 72

JO - Molecular Therapy - Methods and Clinical Development

T2 - Molecular Therapy - Methods and Clinical Development

JF - Molecular Therapy - Methods and Clinical Development

SN - 2329-0501

ER -